Emergence of a norovirus GII.4 strain correlates with changes in evolving blockade epitopes

Journal of Virology

Volumn 87, Issue 5, 2013, Pages 2803-2813

  Lindesmith, Lisa C ^a   Costantini, Verónica ^b   Swanstrom, Jesica ^a   Debbink, Kari ^c   Donaldson, Eric F ^a   Vinjé, Jan ^b   Baric, Ralph S ^a,c  

^a The University of North Carolina at Chapel Hill   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIGENICITY; ARTICLE; CONTROLLED STUDY; EPIDEMIC; HERD IMMUNITY; HUMAN; MOUSE; NONHUMAN; NOROVIRUS; NOROVIRUS INFECTION; PRIORITY JOURNAL; STRAIN DIFFERENCE; VIRUS LIKE AGENT; VIRUS STRAIN;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; CALICIVIRIDAE INFECTIONS; CAPSID PROTEINS; DISEASE OUTBREAKS; EPITOPES; EVOLUTION, MOLECULAR; HUMANS; IMMUNITY, HERD; MICE; NOROVIRUS;

EID: 84874689661     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03106-12     Document Type: Article

References (57)

1. CDC. 2011. Updated norovirus outbreak management and disease prevention guidelines. MMWR Recomm. Rep. 60:1-18.
2. Hutson AM, Atmar RL, Estes MK. 2004. Norovirus disease: changing epidemiology and host susceptibility factors. Trends Microbiol. 12:279-287.
3. Estes MK, Prasad BV, Atmar RL. 2006. Noroviruses everywhere: has something changed? Curr. Opin. Infect. Dis. 19:467-474.
4. Koopmans M, Vinj de Wit JM, Leenen I, van der Poel W, van Duyn-hoven Y. 2000. Molecular epidemiology of human enteric caliciviruses in the Netherlands. J. Infect. Dis. 181(Suppl 2):S262-S269.
5. CDC. 2007. Norovirus activity-United States, 2006 -2007. MMWR Morb. Mortal. Wkly. Rep. 56:842-846.
6. Okada M, Tanaka T, Oseto M, Takeda N, Shinozaki K. 2006. Genetic analysis of noroviruses associated with fatalities in healthcare facilities. Arch. Virol. 151:1635-1641.
7. Harris JP, Edmunds WJ, Pebody R, Brown DW, Lopman BA. 2008. Deaths from norovirus among the elderly, England and Wales. Emerg. Infect. Dis. 14:1546-1552.
8. Schorn R, Hohne M, Meerbach A, Bossart W, Wuthrich RP, Schreier E, Muller NJ, Fehr T. 2010. Chronic norovirus infection after kidney transplantation: molecular evidence for immune-driven viral evolution. Clin. Infect. Dis. 51:307-314.
9. Hall AJ, Eisenbart VG, Etingue AL, Gould LH, Lopman BA, Parashar UD. 2012. Epidemiology of foodborne norovirus outbreaks, United States, 2001-2008. Emerg. Infect. Dis. 18:1566-1573.
10. Patel MM, Widdowson MA, Glass RI, Akazawa K, Vinje J, Parashar UD. 2008. Systematic literature review of role of noroviruses in sporadic gastroenteritis. Emerg. Infect. Dis. 14:1224-1231.
11. Zanini B, Ricci C, Bandera F, Caselani F, Magni A, Laronga AM, Lanzini A. 2012. Incidence of post-infectious irritable bowel syndrome and functional intestinal disorders following a water-borne viral gastroenteritis outbreak. Am. J. Gastroenterol. 107:891-899.
12. Atmar RL, Bernstein DI, Harro CD, Al-Ibrahim MS, Chen WH, Ferreira J, Estes MK, Graham DY, Opekun AR, Richardson C, Mendelman PM. 2011. Norovirus vaccine against experimental human Norwalk virus illness. N. Engl. J. Med. 365:2178-2187.
13. Zheng DP, Ando T, Fankhauser RL, Beard RS, Glass RI, Monroe SS. 2006. Norovirus classification and proposed strain nomenclature. Virology 346:312-323.
14. Prasad BV, Hardy ME, Dokland T, Bella J, Rossmann MG, Estes MK. 1999. X-ray crystallographic structure of the Norwalk virus capsid. Science 286:287-290.
15. Glass PJ, White LJ, Ball JM, Leparc-Goffart I, Hardy ME, Estes MK. 2000. Norwalk virus open reading frame 3 encodes a minor structural protein. J. Virol. 74:6581-6591.
16. Lindesmith LC, Donaldson EF, Lobue AD, Cannon JL, Zheng DP, Vinje J, Baric RS. 2008. Mechanisms of GII.4 norovirus persistence in human populations. PLoS Med. 5:e31. doi:10.1371/journal.pmed.0050031.
17. Chen R, Neill JD, Estes MK, Prasad BV. 2006. X-ray structure of a native calicivirus: structural insights into antigenic diversity and host specificity. Proc. Natl. Acad. Sci. U. S. A. 103:8048-8053.
18. Lochridge VP, Jutila KL, Graff JW, Hardy ME. 2005. Epitopes in the P2 domain of norovirus VP1 recognized by monoclonal antibodies that block cell interactions. J. Gen. Virol. 86:2799-2806.
19. Cao S, Lou Z, Tan M, Chen Y, Liu Y, Zhang Z, Zhang XC, Jiang X, Li X, Rao Z. 2007. Structural basis for the recognition of blood group trisaccharides by norovirus. J. Virol. 81:549-557.
20. Lindesmith LC, Beltramello M, Donaldson EF, Corti D, Swanstrom J, Debbink K, Lanzavecchia A, Baric RS. 2012. Immunogenetic mechanisms driving norovirus GII.4 antigenic variation. PLoS Pathog. 8:e1002705. doi:10.1371/journal.ppat.1002705.
21. Lindesmith LC, Debbink K, Swanstrom J, Vinje J, Costantini V, Baric RS, Donaldson EF. 2012. Monoclonal antibody-based antigenic mapping of norovirus GII.4-2002. J. Virol. 86:873-883.
22. Debbink K, Donaldson EF, Lindesmith LC, Baric RS. 2012. Genetic mapping of a highly variable norovirus GII.4 blockade epitope: potential role in escape from human herd immunity. J. Virol. 86:1214-1226.
23. Siebenga JJ, Vennema H, Renckens B, de Bruin E, van der Veer B, Siezen RJ, Koopmans M. 2007. Epochal evolution of GGII.4 norovirus capsid proteins from 1995 to 2006. J. Virol. 81:9932-9941.
24. Bull RA, Eden JS, Rawlinson WD, White PA. 2010. Rapid evolution of pandemic noroviruses of the GII.4 lineage. PLoS Pathog. 6:e1000831. doi: 10.1371/journal.ppat.1000831.
25. Bok K, Abente EJ, Realpe-Quintero M, Mitra T, Sosnovtsev SV, Kapikian AZ, Green KY. 2009. Evolutionary dynamics of GII.4 noroviruses over a 34-year period. J. Virol. 83:11890-11901.
26. Shanker S, Choi JM, Sankaran B, Atmar RL, Estes MK, Prasad BV. 2011. Structural analysis of HBGA binding specificity in a norovirus GII.4 epidemic variant: implications for epochal evolution. J. Virol. 85:8635-8645.
27. Allen DJ, Gray JJ, Gallimore CI, Xerry J, Iturriza-Gomara M. 2008. Analysis of amino acid variation in the P2 domain of the GII-4 norovirus VP1 protein reveals putative variant-specific epitopes. PLoS One 3:e1485. doi:10.1371/journal.pone.0001485.
28. de Rougemont A, Ruvoen-Clouet N, Simon B, Estienney M, Elie-Caille C, Aho S, Pothier P, Le Pendu J, Boireau W, Belliot G. 2011. Qualitative and quantitative analysis of the binding of GII.4 norovirus variants onto human blood group antigens. J. Virol. 85:4057-4070.
29. Cannon JL, Lindesmith LC, Donaldson EF, Saxe L, Baric RS, Vinje J. 2009. Herd immunity to GII.4 noroviruses is supported by outbreak patient sera. J. Virol. 83:5363-5374.
30. Harrington PR, Lindesmith L, Yount B, Moe CL, Baric RS. 2002. Binding of Norwalk virus-like particles to ABH histo-blood group antigens is blocked by antisera from infected human volunteers or experimentally vaccinated mice. J. Virol. 76:12335-12343.
31. Lindesmith LC, Donaldson E, Leon J, Moe CL, Frelinger JA, Johnston RE, Weber DJ, Baric RS. 2010. Heterotypic humoral and cellular immune responses following Norwalk virus infection. J. Virol. 84:1800-1815.
32. Bok K, Parra GI, Mitra T, Abente E, Shaver CK, Boon D, Engle R, Yu C, Kapikian AZ, Sosnovtsev SV, Purcell RH, Green KY. 2011. Chimpanzees as an animal model for human norovirus infection and vaccine development. Proc. Natl. Acad. Sci. U. S. A. 108:325-330.
33. Reeck A, Kavanagh O, Estes MK, Opekun AR, Gilger MA, Graham DY, Atmar RL. 2010. Serological correlate of protection against norovirusinduced gastroenteritis. J. Infect. Dis. 202:1212-1218.
34. Lindesmith LC, Donaldson EF, Baric RS. 2011. Norovirus GII.4 strain antigenic variation. J. Virol. 85:231-242.
35. Noel JS, Fankhauser RL, Ando T, Monroe SS, Glass RI. 1999. Identification of a distinct common strain of "Norwalk-like viruses" having a global distribution. J. Infect. Dis. 179:1334-1344.
36. Vinje J, Altena S, Koopmans M. 1997. The incidence and genetic variability of small round-structured viruses in outbreaks of gastroenteritis in the Netherlands. J. Infect. Dis. 176:1374-1378.
37. Widdowson MA, Cramer EH, Hadley L, Bresee JS, Beard RS, Bulens SN, Charles M, Chege W, Isakbaeva E, Wright JG, Mintz E, Forney D, Massey J, Glass RI, Monroe SS. 2004. Outbreaks of acute gastroenteritis on cruise ships and on land: identification of a predominant circulating strain of norovirus-United States, 2002. J. Infect. Dis. 190:27-36.
38. Bull RA, Tu ET, McIver CJ, Rawlinson WD, White PA. 2006. Emergence of a new norovirus genotype II.4 variant associated with global outbreaks of gastroenteritis. J. Clin. Microbiol. 44:327-333.
39. Kroneman A, Vennema H, Harris J, Reuter G, von Bonsdorff CH, Hedlund KO, Vainio K, Jackson V, Pothier P, Koch J, Schreier E, Bottiger BE, Koopmans M. 2006. Increase in norovirus activity reported in Europe. Euro Surveill. 11:E061214-061211.
40. Phan TG, Kuroiwa T, Kaneshi K, Ueda Y, Nakaya S, Nishimura S, Yamamoto A, Sugita K, Nishimura T, Yagyu F, Okitsu S, Muller WE, Maneekarn N, Ushijima H. 2006. Changing distribution of norovirus genotypes and genetic analysis of recombinant GIIb among infants and children with diarrhea in Japan. J. Med. Virol. 78:971-978.
41. Siebenga J, Kroneman A, Vennema H, Duizer E, Koopmans M. 10 January 2008. Food-borne viruses in Europe network report: the norovirus GII.4 2006b (for US named Minerva-like, for Japan Kobe034-like, for UK V6) variant now dominant in early seasonal surveillance. Euro Surveill. 13(2):pii=8009. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=8009.
42. Vega EBL, Gregoricus N, Williams K, Lee D, Vinjé J. 2011. Novel surveillance network for norovirus gastroenteritis outbreaks, United States. Emerg. Infect. Dis. 17:1389-1395.
43. Yen C, Wikswo ME, Lopman BA, Vinje J, Parashar UD, Hall AJ. 2011. Impact of an emergent norovirus variant in 2009 on norovirus outbreak activity in the United States. Clin. Infect. Dis. 53:568-571.
44. Donaldson EF, Lindesmith LC, Lobue AD, Baric RS. 2008. Norovirus pathogenesis: mechanisms of persistence and immune evasion in human populations. Immunol. Rev. 225:190-211.
45. Siebenga JJ, Lemey P, Kosakovsky Pond SL, Rambaut A, Vennema H, Koopmans M. 2010. Phylodynamic reconstruction reveals norovirus GII.4 epidemic expansions and their molecular determinants. PLoS Pathog. 6:e1000884. doi:10.1371/journal.ppat.1000884.
46. Allen DJ, Noad R, Samuel D, Gray JJ, Roy P, Iturriza-Gomara M. 2009. Characterisation of a GII-4 norovirus variant-specific surface-exposed site involved in antibody binding. Virol. J. 6:150.
47. Zakikhany K, Allen DJ, Brown D, Iturriza-Gomara M. 2012. Molecular evolution of GII-4 norovirus strains. PLoS One 7:e41625. doi:10.1371 /journal.pone.0041625.
48. Hansman GS, Taylor DW, McLellan JS, Smith TJ, Georgiev I, Tame JR, Park SY, Yamazaki M, Gondaira F, Miki M, Katayama K, Murata K, Kwong PD. 2012. Structural basis for broad detection of genogroup II noroviruses by a monoclonal antibody that binds to a site occluded in the viral particle. J. Virol. 86:3635-3646.
49. Tian P, Yang D, Jiang X, Zhong W, Cannon JL, Burkhardt Iii W, Woods JW, Hartman G, Lindesmith L, Baric RS, Mandrell R. 2010. Specificity and kinetics of norovirus binding to magnetic bead-conjugated histo-blood group antigens. J. Appl. Microbiol. 109:1753-1762.
50. Vinje J, Hamidjaja RA, Sobsey MD. 2004. Development and application of a capsid VP1 (region D) based reverse transcription PCR assay for genotyping of genogroup I and II noroviruses. J. Virol. Methods 116:109-117.
51. Kojima S, Kageyama T, Fukushi S, Hoshino FB, Shinohara M, Uchida K, Natori K, Takeda N, Katayama K. 2002. Genogroup-specific PCR primers for detection of Norwalk-like viruses. J. Virol. Methods 100:107-114.
52. Van de Peer Y, De Wachter R. 1994. TREECON for Windows: a software package for the construction and drawing of evolutionary trees for the Microsoft Windows environment. Comput. Appl. Biosci. 10:569-570.
53. Lochridge VP, Hardy ME. 2007. A single-amino-acid substitution in the P2 domain of VP1 of murine norovirus is sufficient for escape from antibody neutralization. J. Virol. 81:12316-12322.
54. Wang TT, Tan GS, Hai R, Pica N, Petersen E, Moran TM, Palese P. 2010. Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. PLoS Pathog. 6:e1000796. doi:10.1371/journal.ppat.1000796.
55. Yu X, Tsibane T, McGraw PA, House FS, Keefer CJ, Hicar MD, Tumpey TM, Pappas C, Perrone LA, Martinez O, Stevens J, Wilson IA, Aguilar PV, Altschuler EL, Basler CF, Crowe JE, Jr. 2008. Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors. Nature 455:532-536.
56. Dormitzer PR, Galli G, Castellino F, Golding H, Khurana S, Del Giudice G, Rappuoli R. 2011. Influenza vaccine immunology. Immunol. Rev. 239:167-177.
57. Quaranta MG, Mattioli B, Vella S. 2012. Glances in immunology of HIV and HCV infection. Adv. Virol. 2012:434-436.